D. E. Shaw & Co. Inc. Makes New Investment in Indivior PLC (NASDAQ:INDV)

D. E. Shaw & Co. Inc. bought a new position in Indivior PLC (NASDAQ:INDV - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 99,606 shares of the company's stock, valued at approximately $1,238,000. D. E. Shaw & Co. Inc. owned 0.07% of Indivior as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Deutsche Bank AG increased its position in shares of Indivior by 14.2% in the 4th quarter. Deutsche Bank AG now owns 288,473 shares of the company's stock valued at $3,586,000 after buying an additional 35,953 shares in the last quarter. Deerfield Management Company L.P. Series C increased its holdings in shares of Indivior by 74.4% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock worth $110,418,000 after acquiring an additional 3,790,518 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Indivior during the fourth quarter worth about $2,722,000. Balyasny Asset Management L.P. lifted its holdings in shares of Indivior by 142.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 36,381 shares of the company's stock valued at $452,000 after purchasing an additional 21,379 shares in the last quarter. Finally, Alta Fundamental Advisers LLC lifted its holdings in shares of Indivior by 23.1% during the 4th quarter. Alta Fundamental Advisers LLC now owns 400,000 shares of the company's stock valued at $4,972,000 after purchasing an additional 75,000 shares in the last quarter. 60.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on INDV shares. Rodman & Renshaw began coverage on shares of Indivior in a report on Tuesday, January 28th. They set a "buy" rating and a $16.00 target price on the stock. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Piper Sandler cut their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

Indivior Stock Performance

Indivior stock traded up $0.23 during midday trading on Wednesday, reaching $12.06. The stock had a trading volume of 162,863 shares, compared to its average volume of 1,021,379. The stock has a market capitalization of $1.66 billion, a P/E ratio of -34.25 and a beta of 0.98. The firm's fifty day simple moving average is $10.34 and its 200-day simple moving average is $10.72. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. On average, sell-side analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.